PRTN3 and glioblastoma: Some patients had 2 different types of auto-antibodies, and overall, the participants had 43 autoantibodies; 15 patients were anti-MPO positive, 15 were anti-PR3 positive, 3 were anti-GBM positive, 3 were anti-MPO and anti-GBM double positive, 1 was anti-PR3 and anti-GBM double positive, and 1 had both anti-MPO and anti-PR3 antibodies.